Yungjin Pharm Co Ltd (KO:003520) — Market Cap & Net Worth
Market Cap & Net Worth: Yungjin Pharm Co Ltd (003520)
Yungjin Pharm Co Ltd (KO:003520) has a market capitalization of $126.42 Million (₩186.55 Billion) as of October 14, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18349 globally and #830 in its home market, demonstrating a -0.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yungjin Pharm Co Ltd's stock price ₩1020.00 by its total outstanding shares 182892454 (182.89 Million).
Yungjin Pharm Co Ltd Market Cap History: 2015 to 2026
Yungjin Pharm Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $264.00 Million to $126.42 Million (-6.60% CAGR). Check Yungjin Pharm Co Ltd stock price for real-time trading data and today's change.
Yungjin Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yungjin Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Yungjin Pharm Co Ltd (003520) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.00x
Yungjin Pharm Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.20x
Yungjin Pharm Co Ltd's market cap is 0.20 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $264.00 Million | $170.20 Billion | $3.39 Billion | 0.00x | 0.08x |
| 2016 | $1.09 Billion | $193.13 Billion | $4.20 Billion | 0.01x | 0.26x |
| 2017 | $1.09 Billion | $195.01 Billion | $1.87 Billion | 0.01x | 0.58x |
| 2018 | $736.23 Million | $186.41 Billion | -$6.10 Billion | 0.00x | N/A |
| 2019 | $821.75 Million | $220.52 Billion | $5.03 Billion | 0.00x | 0.16x |
| 2020 | $996.51 Million | $208.46 Billion | -$133.12 Million | 0.00x | N/A |
| 2021 | $655.66 Million | $196.07 Billion | -$11.58 Billion | 0.00x | N/A |
| 2022 | $402.82 Million | $218.38 Billion | -$21.96 Billion | 0.00x | N/A |
| 2023 | $263.38 Million | $234.90 Billion | -$3.88 Billion | 0.00x | N/A |
| 2024 | $246.40 Million | $252.04 Billion | $1.23 Billion | 0.00x | 0.20x |
Competitor Companies of 003520 by Market Capitalization
Companies near Yungjin Pharm Co Ltd in the global market cap rankings as of October 14, 2026. See Yungjin Pharm Co Ltd (003520) net asset quality to understand what proportion of total assets are financed by equity.
Key companies related to Yungjin Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #526 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #581 globally with a market cap of $46.88 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #634 globally with a market cap of $42.99 Billion USD ( CN¥293.75 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #526 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #581 | GALDERMA GROUP AG | NYSE:GALDY | $46.88 Billion | $40.21 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.60 |
| #634 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.99 Billion | CN¥46.05 |
Yungjin Pharm Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Yungjin Pharm Co Ltd's market cap moved from $264.00 Million to $ 126.42 Million, with a yearly change of -6.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩126.42 Million | -49.00% |
| 2025 | ₩247.89 Million | +0.60% |
| 2024 | ₩246.40 Million | -6.45% |
| 2023 | ₩263.38 Million | -34.62% |
| 2022 | ₩402.82 Million | -38.56% |
| 2021 | ₩655.66 Million | -34.20% |
| 2020 | ₩996.51 Million | +21.27% |
| 2019 | ₩821.75 Million | +11.62% |
| 2018 | ₩736.23 Million | -32.35% |
| 2017 | ₩1.09 Billion | -0.45% |
| 2016 | ₩1.09 Billion | +314.08% |
| 2015 | ₩264.00 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 13th, 2026 the market cap of Yungjin Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $126.42 Million USD |
| MoneyControl | $126.42 Million USD |
| MarketWatch | $126.42 Million USD |
| marketcap.company | $126.42 Million USD |
| Reuters | $126.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more